Nogo receptor-Fc delivered by haematopoietic cells enhances neurorepair in a multiple sclerosis model

This study explores a new way to treat multiple sclerosis (MS) by using hematopoietic stem cells (HSCs) to deliver a therapeutic protein called Nogo receptor-Fc (NgR-Fc) to the brain. The idea is to help repair the damage caused by MS, specifically the loss of myelin, which protects nerve fibers. The researchers genetically modified HSCs to produce NgR-Fc, which can block the effects of substances that prevent nerve regeneration. These modified cells were then transplanted into mice with a condition similar to MS, called experimental autoimmune encephalomyelitis (EAE). The results showed that the mice receiving the modified HSCs had improved recovery from EAE, with signs of nerve regeneration and myelin repair. This suggests that using HSCs to deliver NgR-Fc could be a promising new approach for treating MS.

• 1
  Transplantation of NgR(310)ecto-Fc-transduced HSCs into EAE mice resulted in significantly reduced clinical scores after the peak stage of disease symptoms, indicating recovery from neurological decline.
• 2
  CD11b+ macrophages were the predominant immune-positive cell type overexpressing myc-tagged Nogo receptor(1-310)-Fc fusion protein at the peak stage of experimental autoimmune encephalomyelitis.
• 3
  The study observed enhanced axonal regeneration and remyelination in the white matter tracts of mice transplanted with haematopoietic stem cells transduced with the lentiviral vector carrying Nogo receptor(1-310)-Fc.